Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)

(2021) Audrey Simonaggio et al.   Cancers

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sequential treatment of metastatic renal cancer in a complex evolving landscape

(2020) Javier C. Angulo et al.   Annals of Translational Medicine

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer

(2020) Alessandra Raimondi et al.   Frontiers in Oncology

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

(2020) Elizabeth C. Paver et al.   PATHOLOGY

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma

(2019) Caroline E. Nunes-Xavier et al.   Current Urology Reports

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

(2019) Benjamin Bian et al.   OncoImmunology

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

(2019) Tetsuro Tominaga et al.   PLoS One

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma

(2019) Xingming Zhang et al.   BMC CANCER

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

(2019) Solène-Florence Kammerer-Jacquet et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy

(2019) Daniele Lecis et al.   Cancers

Application of PD-1 Blockade in Cancer Immunotherapy

(2019) Xiaomo Wu et al.   Computational and Structural Biotechnology Journal

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

(2019) Suzanne L. Topalian et al.   JAMA Oncology

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

(2019) Veronica Mollica et al.   Cancers

Combination therapy with PD-1 or PD-L1 inhibitors for cancer

(2019) Hidetoshi Hayashi et al.   International Journal of Clinical Oncology

The Changing Therapeutic Landscape of Metastatic Renal Cancer

(2019) Javier C. Angulo et al.   Cancers

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients

(2019) Qinchuan Wang et al.   Journal for ImmunoTherapy of Cancer

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma

(2019) Philipp J. Stenzel et al.   Translational Oncology

A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma

(2019) Yukari Bando et al.   BMJ Open

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma

(2019) Jeanette E. Eckel‐Passow et al.   Cancer Medicine

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

(2019) Matteo Santoni et al.   Cancers

Current and Emerging Therapies for First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

(2018) Michael B. Atkins et al.   CANCER TREATMENT REVIEWS

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

(2018) Thomas J. Mitchell et al.   CELL

Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy

(2018) José I. López et al.   PATHOLOGY RESEARCH AND PRACTICE

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

(2018) Diana Miao et al.   SCIENCE

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

(2018) Jason Zhu et al.   Journal for ImmunoTherapy of Cancer

OUP accepted manuscript

(2018)   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma

(2018) Kosuke Ueda et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

(2018) Kathleen M. Mahoney et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression pattern of immune checkpoint–associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

(2017) Takuto Hara et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

Next generation predictive biomarkers for immune checkpoint inhibition

(2016) Yulian Khagi et al.   CANCER AND METASTASIS REVIEWS

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

(2016) C.-Y. Ock et al.   CLINICAL CANCER RESEARCH

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

(2014) T. K. Choueiri et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

(2014) L.B. Jilaveanu et al.   Journal of Cancer

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

(2013) Daniel YC Heng et al.   LANCET ONCOLOGY

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy

(2010) Andrew Dennis Smith et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma

(2010) Francesco Liotta et al.   BJU INTERNATIONAL